SWOBY

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB (SWOBY)

About SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB (SWOBY)

Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceuticals. It operates through the Haematology, Immunology, and Specialty Care segments. The Haemotology segment focuses on haemophilia medicines Elocta and Alprolix. The immunology segment offers treatment for serious, disabling, and life-threatening diseases. The Specialty Care segment specializes in the treatment of genetic and metabolic diseases. The company was founded in 2001 and is headquartered in Solna, Sweden.

Details

Daily high
--
Daily low
--
Price at open
--
52 Week High
$18.20
52 Week Low
$12.75
Market cap
12.3B
Dividend yield
0.00%
Volume
22
Avg. volume
482
P/E ratio
-477.21

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB News

Details

Daily high
--
Daily low
--
Price at open
--
52 Week High
$18.20
52 Week Low
$12.75
Market cap
12.3B
Dividend yield
0.00%
Volume
22
Avg. volume
482
P/E ratio
-477.21